Skip to main content

Drug Interactions between Digitek and Kao-Spen

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

digoxin kaolin

Applies to: Digitek (digoxin) and Kao-Spen (kaolin/pectin)

ADJUST DOSING INTERVAL: Concurrent administration of kaolin-pectin may decrease the oral bioavailability of digitalis glycosides. The mechanism of interaction is unknown. In a single-dose study, simultaneous administration of a kaolin-pectin suspension and an oral dose of digoxin resulted in delay of absorption and a 62% reduction in the bioavailability of digoxin. Intersubject variation in digoxin bioavailability also increased more than twofold in the presence of kaolin-pectin. In contrast, administration of kaolin-pectin 2 hours before the digoxin dose had no effect on digoxin absorption rate but reduced digoxin bioavailability by 20%, while administration 2 hours after the digoxin dose neither affected the rate nor extent of absorption of digoxin. Also, no change in intersubject variability in digoxin bioavailability was observed when administration times were separated. In seven patients receiving chronic oral digoxin therapy, simultaneous administration of a kaolin-pectin antidiarrheal mixture decreased steady-state digoxin peak levels (Cmax) by 36% and the 24-hour area under the concentration-time curve (AUC) by 15%. When kaolin-pectin was administered 2 hours before or 2 hours after digoxin, no evidence of an interaction was observed. In ten healthy volunteers, administration of a single 0.75 mg dose of digoxin with kaolin-pectin significantly reduced the cumulative six-day urinary digoxin excretion (expressed as the percentage of original dose recovered) compared to administration without (23.4% vs. 40.1%). In another study, coadministration with 60 mL of a commercial kaolin-pectin suspension had no effect on the 24-hour AUC of digoxin administered as two 0.2 mg capsules or tablets, although the digoxin Cmax from both formulations was reduced, and the 24-hour digoxin urinary recovery from the tablets tended to be reduced.

MANAGEMENT: To minimize the potential for interaction, patients should be advised to take kaolin-pectin at least 2 hours after digoxin if possible. The same precaution may be applicable during therapy with digitoxin, although clinical data are lacking.

References

  1. Brown DD, Juhl RP "Decreased bioavailability of digoxin due to antacids and kaolin-pectin." N Engl J Med 295 (1976): 1034-7
  2. Rodin SM, Johnson BF "Pharmacokinetic interactions with digoxin." Clin Pharmacokinet 15 (1988): 227-44
  3. Allen MD, Greenblatt DJ, Harmatz JS, Smith TW "Effect of magnesium--aluminum hydroxide and kaolin--pectin on absorption of digoxin from tablets and capsules." J Clin Pharmacol 21 (1981): 26-30
  4. Albert KS, Ayres JW, DiSanto AR, Weidler DJ, Sakmar E, Hallmark MR, Stoll RG, DeSante KA, Wagner JG "Influence of kaolin--pectin suspension on digoxin bioavailability." J Pharm Sci 67 (1978): 1582-6
  5. Marcus FI "Pharmacokinetic interactions between digoxin and other drugs." J Am Coll Cardiol 5 (1985): a82-90
View all 5 references

Switch to consumer interaction data

Moderate

digoxin pectin

Applies to: Digitek (digoxin) and Kao-Spen (kaolin/pectin)

ADJUST DOSING INTERVAL: Concurrent administration of kaolin-pectin may decrease the oral bioavailability of digitalis glycosides. The mechanism of interaction is unknown. In a single-dose study, simultaneous administration of a kaolin-pectin suspension and an oral dose of digoxin resulted in delay of absorption and a 62% reduction in the bioavailability of digoxin. Intersubject variation in digoxin bioavailability also increased more than twofold in the presence of kaolin-pectin. In contrast, administration of kaolin-pectin 2 hours before the digoxin dose had no effect on digoxin absorption rate but reduced digoxin bioavailability by 20%, while administration 2 hours after the digoxin dose neither affected the rate nor extent of absorption of digoxin. Also, no change in intersubject variability in digoxin bioavailability was observed when administration times were separated. In seven patients receiving chronic oral digoxin therapy, simultaneous administration of a kaolin-pectin antidiarrheal mixture decreased steady-state digoxin peak levels (Cmax) by 36% and the 24-hour area under the concentration-time curve (AUC) by 15%. When kaolin-pectin was administered 2 hours before or 2 hours after digoxin, no evidence of an interaction was observed. In ten healthy volunteers, administration of a single 0.75 mg dose of digoxin with kaolin-pectin significantly reduced the cumulative six-day urinary digoxin excretion (expressed as the percentage of original dose recovered) compared to administration without (23.4% vs. 40.1%). In another study, coadministration with 60 mL of a commercial kaolin-pectin suspension had no effect on the 24-hour AUC of digoxin administered as two 0.2 mg capsules or tablets, although the digoxin Cmax from both formulations was reduced, and the 24-hour digoxin urinary recovery from the tablets tended to be reduced.

MANAGEMENT: To minimize the potential for interaction, patients should be advised to take kaolin-pectin at least 2 hours after digoxin if possible. The same precaution may be applicable during therapy with digitoxin, although clinical data are lacking.

References

  1. Brown DD, Juhl RP "Decreased bioavailability of digoxin due to antacids and kaolin-pectin." N Engl J Med 295 (1976): 1034-7
  2. Rodin SM, Johnson BF "Pharmacokinetic interactions with digoxin." Clin Pharmacokinet 15 (1988): 227-44
  3. Allen MD, Greenblatt DJ, Harmatz JS, Smith TW "Effect of magnesium--aluminum hydroxide and kaolin--pectin on absorption of digoxin from tablets and capsules." J Clin Pharmacol 21 (1981): 26-30
  4. Albert KS, Ayres JW, DiSanto AR, Weidler DJ, Sakmar E, Hallmark MR, Stoll RG, DeSante KA, Wagner JG "Influence of kaolin--pectin suspension on digoxin bioavailability." J Pharm Sci 67 (1978): 1582-6
  5. Marcus FI "Pharmacokinetic interactions between digoxin and other drugs." J Am Coll Cardiol 5 (1985): a82-90
View all 5 references

Switch to consumer interaction data

Drug and food interactions

Minor

digoxin food

Applies to: Digitek (digoxin)

Administration of digoxin with a high-fiber meal has been shown to decrease its bioavailability by almost 20%. Fiber can sequester up to 45% of the drug when given orally. Patients should be advised to maintain a regular diet without significant fluctuation in fiber intake while digoxin is being titrated.

Grapefruit juice may modestly increase the plasma concentrations of digoxin. The mechanism is increased absorption of digoxin due to mild inhibition of intestinal P-glycoprotein by certain compounds present in grapefruits. In 12 healthy volunteers, administration of grapefruit juice with and 30 minutes before, as well as 3.5, 7.5, and 11.5 hours after a single digoxin dose (0.5 mg) increased the mean area under the plasma concentration-time curve (AUC) of digoxin by just 9% compared to administration with water. Moreover, P-glycoprotein genetic polymorphism does not appear to influence the magnitude of the effects of grapefruit juice on digoxin. Thus, the interaction is unlikely to be of clinical significance.

References

  1. Darcy PF "Nutrient-drug interactions." Adverse Drug React Toxicol Rev 14 (1995): 233-54
  2. Becquemont L, Verstuyft C, Kerb R, et al. "Effect of grapefruit juice on digoxin pharmacokinetics in humans." Clin Pharmacol Ther 70 (2001): 311-6

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.